{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:26:18Z","timestamp":1790281578487,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2012,9,26]],"date-time":"2012-09-26T00:00:00Z","timestamp":1348617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>The Avastin\u00ae Registry: Investigation of Effectiveness and Safety (ARIES) study is a prospective, community-based observational cohort study that evaluated the effectiveness and safety of first-line treatment patterns, assessing the impact of chemotherapy choice and treatment duration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>The ARIES study enrolled patients with metastatic colorectal cancer (mCRC) receiving first-line chemotherapy with bevacizumab and followed them longitudinally. The protocol did not specify treatment regimens or assessments. Analyses included all patients who initiated bevacizumab in combination with either first-line oxaliplatin with infusional 5-fluorouracil and leucovorin (FOLFOX) or irinotecan with infusional 5-fluorouracil and leucovorin (FOLFIRI). Progression-free survival (PFS) and overall survival (OS) times were estimated using Kaplan\u2013Meier methods. Hazard ratios (HRs) were estimated with multivariate Cox regression analysis, adjusting for potential confounding factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>In total, 1,550 patients with first-line mCRC were enrolled (median follow-up, 21 months) and most received FOLFOX\u2013bevacizumab (n = 968) or FOLFIRI\u2013bevacizumab (n = 243) as first-line therapy. The baseline characteristics and median treatment duration were generally similar between subgroups. There were no significant differences in the median PFS (10.3 months vs. 10.2 months) or OS (23.7 months vs. 25.5 months) time between the FOLFOX\u2013bevacizumab and FOLFIRI\u2013bevacizumab subgroups, respectively, by unadjusted analyses. Multivariate analyses showed FOLFIRI\u2013bevacizumab resulted in a similar PFS (HR, 1.03; 95% confidence interval [CI], 0.88\u20131.21) and OS (HR, 0.95; 95% CI, 0.78\u20131.16) outcome as with FOLFOX\u2013bevacizumab. The incidence proportions of bevacizumab-associated adverse events were similar for FOLFOX- and FOLFIRI-based therapies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions.<\/jats:title>\n                  <jats:p>In first-line mCRC patients, the FOLFOX\u2013bevacizumab and FOLFIRI\u2013bevacizumab regimens were associated with similar treatment patterns and clinical outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2012-0190","type":"journal-article","created":{"date-parts":[[2012,9,27]],"date-time":"2012-09-27T16:14:17Z","timestamp":1348762457000},"page":"1486-1495","source":"Crossref","is-referenced-by-count":85,"title":["Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX\u2013Bevacizumab or FOLFIRI\u2013Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study"],"prefix":"10.1093","volume":"17","author":[{"given":"Johanna C.","family":"Bendell","sequence":"first","affiliation":[{"name":"a Sarah Cannon Research Institute, Nashville, Tennessee, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios S.","family":"Bekaii-Saab","sequence":"additional","affiliation":[{"name":"b The Ohio State University Medical Center, Columbus, Ohio, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen L.","family":"Cohn","sequence":"additional","affiliation":[{"name":"c Rocky Mountain Cancer Center, Denver, Colorado, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert I.","family":"Hurwitz","sequence":"additional","affiliation":[{"name":"d Duke University Medical Center, Durham, North Carolina, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kozloff","sequence":"additional","affiliation":[{"name":"e Ingalls Hospital and University of Chicago, Harvey, Illinois, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haluk","family":"Tezcan","sequence":"additional","affiliation":[{"name":"f Kootenai Cancer Center, Coeur d'Alene, Idaho, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Roach","sequence":"additional","affiliation":[{"name":"g FightColorectalCancer.org, Patient Advocacy, Alexandria, Virginia, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Mun","sequence":"additional","affiliation":[{"name":"h Genentech, Inc., South San Francisco, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Fish","sequence":"additional","affiliation":[{"name":"h Genentech, Inc., South San Francisco, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Dawn","family":"Flick","sequence":"additional","affiliation":[{"name":"h Genentech, Inc., South San Francisco, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshan","family":"Dalal","sequence":"additional","affiliation":[{"name":"h Genentech, Inc., South San Francisco, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Grothey","sequence":"additional","affiliation":[{"name":"i Mayo Clinic College of Medicine, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,9,26]]},"reference":[{"key":"2021122308240705700_B1","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, version 1.2012","author":"National Comprehensive Cancer Network"},{"key":"2021122308240705700_B2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122308240705700_B3","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1200\/JCO.2005.07.113","article-title":"Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale","volume":"23","author":"Colucci","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308240705700_B4","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","article-title":"Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment","volume":"22","author":"Grothey","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122308240705700_B5","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122308240705700_B6","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1200\/JCO.2005.00.232","article-title":"Combined analysis of efficacy: The addition of bevacizumab to fluorouracil\/leucovorin improves survival for patients with metastatic colorectal cancer","volume":"23","author":"Kabbinavar","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308240705700_B7","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308240705700_B8","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2006.06.1317","article-title":"Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup trial","volume":"24","author":"Goldberg","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308240705700_B9","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1200\/JCO.2007.11.3357","article-title":"Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study","volume":"25","author":"Fuchs","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308240705700_B10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.2007.15.5390","article-title":"Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results from the BICC-C study","volume":"26","author":"Fuchs","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308240705700_B11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000229787","article-title":"Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer","volume":"77","author":"Sobrero","year":"2009","journal-title":"Oncology"},{"key":"2021122308240705700_B12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2009.24.8252","article-title":"Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance","volume":"28","author":"Kopetz","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308240705700_B13","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.2007.15.4138","article-title":"Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study","volume":"26","author":"Hochster","year":"2008","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"2021122308240705700_B14","first-page":"170s","article-title":"Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1\/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer","volume":"25","author":"Saltz","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308240705700_B15","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl 8","key":"2021122308240705700_B16","first-page":"viii10","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of hedgehog pathway inhibitor (HPI) GDC-0449 in patients with previously untreated metastatic colorectal cancer (mCRC)","volume":"21","author":"Berlin","year":"2010","journal-title":"Ann Oncol"},{"key":"2021122308240705700_B17","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1634\/theoncologist.2009-0071","article-title":"Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study","volume":"14","author":"Kozloff","year":"2009","journal-title":"The Oncologist"},{"key":"2021122308240705700_B18","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdp233","article-title":"Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study","volume":"20","author":"Cutsem","year":"2009","journal-title":"Ann Oncol"},{"key":"2021122308240705700_B19","volume-title":"Eloxatin [package insert]","year":"2009"},{"key":"2021122308240705700_B20","volume-title":"Camptosar [package insert]","year":"2010"},{"key":"2021122308240705700_B21","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122308240705700_B22","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","article-title":"Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07","volume":"25","author":"Kuebler","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308240705700_B23","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1200\/JCO.2008.16.3212","article-title":"Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE)","volume":"26","author":"Grothey","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021122308240705700_B24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0959-8049(11)71658-6","article-title":"Cumulative exposure to bevacizumab (BV) after progression correlates with increased survival in patients (pts) with metastatic colorectal cancer (mCRC): A time-dependent analysis of the ARIES observational cohort study","volume":"47","author":"Grothey","year":"2011","journal-title":"Eur J Cancer"},{"key":"2021122308240705700_B25","volume-title":"Investor Update: Avastin-Based Regimen Extends Survival When Continued Beyond Initial Treatment in Patients with Metastatic Colorectal Cancer","author":"Hoffman-La Roche"},{"key":"2021122308240705700_B26","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2010.32.3220","article-title":"Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of patients in randomized phase II and III studies","volume":"29","author":"Hurwitz","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308240705700_B27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1200\/JCO.1998.16.1.309","article-title":"ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy","volume":"16","author":"Metzger","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122308240705700_B28","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2011.29","article-title":"TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials","author":"Grimminger","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"2021122308240705700_B29","volume-title":"Study of Bevacizumab\/mFOLFOX6 Versus Bevacizumab\/FOLFIRI with Biomarker Stratification in Patients with Previously Untreated Metastatic Colorectal Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2012-0190","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2012-0190","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/12\/1486\/41860327\/oncolo_17_12_1486.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/12\/1486\/41860327\/oncolo_17_12_1486.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T22:22:18Z","timestamp":1640298138000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/12\/1486\/6403280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,26]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,9,26]]},"published-print":{"date-parts":[[2012,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2012-0190","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,12,1]]},"published":{"date-parts":[[2012,9,26]]}}}